CN112891512A - Application of polypeptide compound in preventing or treating hepatic fibrosis - Google Patents
Application of polypeptide compound in preventing or treating hepatic fibrosis Download PDFInfo
- Publication number
- CN112891512A CN112891512A CN202110087285.7A CN202110087285A CN112891512A CN 112891512 A CN112891512 A CN 112891512A CN 202110087285 A CN202110087285 A CN 202110087285A CN 112891512 A CN112891512 A CN 112891512A
- Authority
- CN
- China
- Prior art keywords
- cys
- lys
- compound
- ser
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 74
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 68
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 68
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 68
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229940125904 compound 1 Drugs 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 10
- 229940126214 compound 3 Drugs 0.000 claims description 10
- 229940125898 compound 5 Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims 1
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 abstract description 7
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 13
- 208000019425 cirrhosis of liver Diseases 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 4
- DXHINQUXBZNUCF-MELADBBJSA-N Asn-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O DXHINQUXBZNUCF-MELADBBJSA-N 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 description 4
- WZJLBUPPZRZNTO-CIUDSAMLSA-N Cys-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N WZJLBUPPZRZNTO-CIUDSAMLSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 description 4
- ODXKUIGEPAGKKV-KATARQTJSA-N Thr-Leu-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N)O ODXKUIGEPAGKKV-KATARQTJSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FBDBXJJQMHPGMP-FNFFQOHASA-N [(2s)-2-hydroxy-3-[hydroxy-[(2r,3r,5s,6r)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] acetate Chemical compound CC(=O)OC[C@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O FBDBXJJQMHPGMP-FNFFQOHASA-N 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000013424 sirius red staining Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010065441 Venous haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an application of a polypeptide compound in preparing a medicament for preventing or treating hepatic fibrosis, wherein the polypeptide compound contains an amino acid sequence as follows: Cys-Xaa2-Lys-Asn-Xaa5-Xaa6-Thr-Xaa8-Cys-COR1(ii) a Wherein R is1=‑NH2or-OH; xaa2 ═ Lys or Ser; xaa5 ═ Ser or Tyr; xaa6 ═ Pro or Lys; xaa8 ═ Leu or Ala. The polypeptide compound targets GPR55, and a large number of experimental studies prove that the polypeptide compound can obviously improve hepatic fibrosis and can be applied to preparation of medicaments for preventing or treating hepatic fibrosis.
Description
Technical Field
The invention belongs to the technical field of biochemistry, and particularly relates to a new application of a polypeptide compound, namely an application of the polypeptide compound in treating or preventing hepatic fibrosis.
Background
Hepatic fibrosis is a progressive chronic liver disease that eventually progresses to cirrhosis (Don C, Rocky PDB, Joseph A. fibrosis-A common pathway to organ in liver failure [ J ]. New England and Journal of Medi-cine,2015,372(12):1138 and 1149). Various stimuli can cause chronic liver diseases such as toxins, viruses, cholestasis, hypoxia or harmful metabolites, etc. When stimulation is repeated or sustained over a long period of time, the injury increases collagen content in the extracellular matrix (ECM) and drives progressive fibrosis by inducing fibrogenic cytokines/growth factors and other mediators that activate downstream effectors of fibrosis. Collagen is the most abundant ECM component in fibrosis, increases by 10-fold in cirrhosis, and many ECM molecules can be used as both an index and a target for treatment of fibrosis. Wherein hepatic stellate cells, fibroblasts and sinus endothelial cells are stimulated to be activated in large amounts to produce harmful metabolites. With the progression of the disease process, in advanced fibrosis, the extracellular matrix is fibrotic by collagen (type I, type III and type V) secreted by activated hepatic stellate cells and fibroblasts, as well as other proteins constituting pathological fibrous tissues.
At present, the intervention drugs and therapies aiming at the etiology of hepatic fibrosis mainly comprise the following medicines: (1) specific inhibition of collagen synthesis therapy; (2) inhibition of collagen crosslinking therapy with lysyl oxidase and tissue transglutaminase; (3) small interfering RNA, antisense oligonucleotide and liver targeting nanocarrier therapy; (4) an integrin; (5) targeted Fibroblast Activity Protein (FAP) therapy. Although there are numerous drugs for treating hepatic fibrosis instead today, there are still no targeted drugs and therapies (Modern Practical Medicine, November 2020, vol.32, No.11 advances in anti-fibrosis and targeted drug therapy for hepatic fibrosis treatment, wangsi, chengili, fenpiceid).
GPR55 is a cannabinoid receptor expressed primarily in the pancreas, adipose tissue, gastrointestinal tract, liver and brain. Lysophosphatidylinositol is an endogenous ligand of GPR55, which binds to GPR55 and activates its downstream pathways, such as the RhoA-ROCK pathway and calcium ion release (Tuduri E, Imbernon M, Hernandez-Bautista RJ, Tojo M, Ferno J, Dieguez C, nogueras r.gpr55: a new formulating target for metablism J Mol Endocrinol 2017; 58: R191-R202). In recent years, it has been reported that the LPI/GPR55 system plays a crucial role in the development of nonalcoholic fatty liver diseases (Fondervia MF, FernandeZ U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, Gonzalez-Rodriguez A, Alonso C, et al. the L-alpha-lysophosphatdylisinosite/GPR 55system indexes of the grade of non-alcoholic steatosides and steatopathies. hepatology 2020). Therefore, GPR55 may be a potential therapeutic target for alleviating chronic liver disease.
Disclosure of Invention
The invention aims to provide a new application of a polypeptide compound, namely an application of the polypeptide compound in preventing or treating hepatic fibrosis. The polypeptide compound targets GPR55, and a large number of experimental studies prove that the polypeptide compound can obviously improve hepatic fibrosis and can be applied to preparation of medicaments for preventing or treating hepatic fibrosis.
To achieve the above object, the present invention provides an application of a polypeptide compound in preparing a medicament for preventing or treating liver fibrosis, wherein the polypeptide compound comprises the following amino acid sequences:
Cys-Xaa2-Lys-Asn-Xaa5-Xaa6-Thr-Xaa8-Cys-COR1
wherein R is1=-NH2or-OH;
xaa2 ═ Lys or Ser;
xaa5 ═ Ser or Tyr;
xaa6 ═ Pro or Lys;
xaa8 ═ Leu or Ala.
The polypeptide compound of the present invention, preferably Xaa6 ═ Pro.
The polypeptide compound of the present invention is preferably Xaa2 ═ Lys.
The polypeptide compound of the present invention is any one of the following compounds 1 to 8:
compound 1(SEQ ID NO. 1):
Cys-Lys-Lys-Asn-Ser-Pro-Thr-Ala-Cys
CKKNSPTAC
compound 2(SEQ ID NO. 2):
Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Leu-Cys
CKKNYPTLC
compound 3(SEQ ID NO. 3):
Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Ala-Cys
CKKNYPTAC
compound 4(SEQ ID NO. 4):
Cys-Lys-Lys-Asn-Ser-Pro-Thr-Leu-Cys
CKKNSPTLC
compound 5(SEQ ID NO. 5):
Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Leu-Cys
CSKNYPTLC
compound 6(SEQ ID NO. 6):
Cys-Ser-Lys-Asn-Ser-Pro-Thr-Leu-Cys
CSKNSPTLC
compound 7(SEQ ID NO. 7):
Cys-Ser-Lys-Asn-Ser-Pro-Thr-Ala-Cys
CSKNSPTAC
compound 8(SEQ ID NO. 8):
Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Ala-Cys
CSKNYPTAC。
another aspect of the present invention is to provide a composition comprising the above polypeptide compound.
The composition is a pharmaceutical composition, and the polypeptide compound is used as an active ingredient and is added with a pharmaceutically acceptable carrier and/or an auxiliary material to prepare the pharmaceutical composition.
Cell and animal experiments show that the polypeptide compound of the invention has no adverse reaction and can be used for preventing or treating hepatic fibrosis.
It will be appreciated by those skilled in the art that the pharmaceutical compositions of the present invention are suitable for various modes of administration, such as oral, transdermal, intravenous, intramuscular, topical, nasal, and the like. Depending on the mode of administration employed, the pharmaceutical compositions of the polypeptide compounds of the present invention may be formulated into various suitable dosage forms comprising at least one effective dose of the polypeptide compound of the present invention and at least one pharmaceutically acceptable carrier. Examples of suitable dosage forms are tablets, capsules, sugar-coated tablets, granules, oral solutions and syrups, ointments and patches for the skin surface, aerosols, nasal sprays, and sterile solutions for injection.
Pharmaceutical compositions containing the polypeptide compounds of the present invention may be formulated as solutions or lyophilized powders for parenteral administration, which powders may be reconstituted with a suitable solvent or other pharmaceutically acceptable carrier prior to use, and liquid formulations are typically buffers, isotonic and aqueous solutions.
The amount of the pharmaceutical composition of the present invention may vary over a wide range and can be readily determined by one skilled in the art based on objective factors such as the type of disease, the severity of the condition, the weight of the patient, the dosage form, and the route of administration.
The invention has the advantages that:
1) the polypeptide compound of the invention has good biological activity;
2) the polypeptide compound can obviously improve hepatic fibrosis and has good treatment effect on the hepatic fibrosis;
3) the polypeptide compound of the invention shows significant pharmaceutical activity in the drug-induced experiments;
4) the polypeptide compound of the invention shows good safety and stability in the pharmaceutical experiment;
5) the polypeptide compound has high synthesis yield, good stability, easy scale-up production and low cost.
Abbreviations used in the present invention have the following specific meanings:
fmoc is fluorenylmethyloxycarbonyl, resin is resin, mPEG is monomethoxy polyethylene glycol, Cys is cysteine, Lys is lysine, Ser is serine, Asn is asparagine, Tyr is tyrosine, Thr is threonine, Ala is alanine, Leu is leucine, and Pro is proline.
Drawings
FIG. 1 shows the process at CCl4In the induced hepatic fibrosis model of mouse liver, H of mouse liver after administration of 150. mu.g/kg of Compound 1, Compound 2, Compound 3, Compound 4, Compound 5 and Compound 6, respectively&E staining pathological section picture.
FIG. 2 shows the result of the measurement in CCl4Sirius red stained pathological section images of mouse livers after administration of 150 μ g/kg of compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6, respectively, in an induced mouse liver fibrosis model.
FIG. 3 shows the result of the analysis of the signal at CCl4Histogram analysis of liver lipid accumulation in mice following administration of 150 μ g/kg of compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6, respectively, in the induced mouse liver fibrosis model.
FIG. 4 shows the result of the comparison between CCl4Collagen1 immunohistochemical pathological section images of mouse liver after administration of 150 μ g/kg of compound 1, compound 2, compound 3, compound 4, compound 5, and compound 6, respectively, in the induced mouse liver fibrosis model.
FIG. 5 shows the result of the comparison between CCl4Histogram analysis of liver lipid accumulation in mice following administration of 150 μ g/kg of compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6, respectively, in the induced mouse liver fibrosis model.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Example 1Synthesis of polypeptide Compounds
Materials:
all amino acids were purchased from gill biochemical (shanghai) ltd. All other reagents were analytically pure, Sigma brand, if not otherwise specified. Protein Technologies PRELUDE 6 channel polypeptide synthesizer was used. Phenomenex Luna C18 preparative columns (46 mm. times.250 mm) were used to purify the polypeptides. The high performance liquid chromatograph is a product of Waters company. Mass spectrometry was performed using an Agilent mass spectrometer.
The experimental method comprises the following steps:
the compound is synthesized from a carboxyl terminal to an amino terminal by adopting an Fmoc solid-phase polypeptide synthesis method and is sequentially connected according to the sequence of the amino acid sequence. The method comprises the following specific steps: firstly, MBHAR (Amide-MBHA-Resin Amide protected MBHA Resin) or Wang Resin is adopted to remove Fmoc protecting group for synthesis. And (3) detecting by using an indene detection reagent, wherein the use amount of the indene detection reagent is that the reagent 1: reagent 2: reagent 3 ═ l: 2: l (dropping), heating in boiling water for 3-10 min. Treating resin, weighing a certain amount of MBHA resin in a synthesizer, adding DCM, stirring for 30min, draining, washing with DMF for 4 times, each time for 2min, picking out a small amount of resin, performing indene detection, and if the resin color is not changed, indicating normal, using. Removing Fmoc protection: the 20% piperidine was washed 4 times, and after the 3 rd wash, it was indenylated, indicating that the next amino acid was accessible if the indenylated color appeared bluish-purple. Repeating the operation until the peptide synthesis is completed. Finally, washing the polypeptide after precipitation and cutting by utilizing ethyl acetate, and then purifying by high performance liquid chromatography.
Based on the above synthetic procedures, the following polypeptide compounds of the present invention were synthesized (table 1):
table 1. structure of the polypeptide compound synthesized in the examples of the present invention:
compound (I) | Numbering | Sequence of |
1 | SEQ ID NO.1 | Cys-Lys-Lys-Asn-Ser-Pro-Thr-Ala- |
2 | SEQ ID NO.2 | Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Leu- |
3 | SEQ ID NO.3 | Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Ala- |
4 | SEQ ID NO.4 | Cys-Lys-Lys-Asn-Ser-Pro-Thr-Leu- |
5 | SEQ ID NO.5 | Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Leu- |
6 | SEQ ID NO.6 | Cys-Ser-Lys-Asn-Ser-Pro-Thr-Leu-Cys |
7 | SEQ ID NO.7 | Cys-Ser-Lys-Asn-Ser-Pro-Thr-Ala-Cys |
8 | SEQ ID NO.8 | Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Ala-Cys |
Example 2The polypeptide Compound of the present invention para carbon tetrachloride (CCl)4) Improvement and treatment effect of induced mouse hepatic fibrosis
In this embodiment, the polypeptide compound 1, the polypeptide compound 2, the polypeptide compound 3, the polypeptide compound 4, the polypeptide compound 5, and the polypeptide compound 6 are selected as examples to study the effect of the polypeptide compound of the present invention on improving and treating liver fibrosis in mice, and the specific method is as follows.
1. The tested drugs are: polypeptide compound analogs. The storage conditions were-20 ℃.
The molding method comprises the following steps: 48 male C57BL/6J mice, male, with a weight of 18-22g and a week age of 8 weeks (purchased from Beijing Wintonliflam laboratory animals technologies, Inc.), were randomly divided into 8 groups, each consisting of: 1) control group (Oil) + normal saline, i.e. intraperitoneal injection, n-6; 2) model control group (CCl)4) Normal saline, intraperitoneal injection, n is 6; administration of CCl to mice4Once in three days for 6 weeks; 3) model administration group (CCl)4) +150 μ g/kg of polypeptide compound 1, i.p., n ═ 6/group; 4) model administration group (CCl)4) +150 μ g/kg of polypeptide compound 2, i.p., n ═ 6/group; 5) model administration group (CCl)4) +150 μ g/kg of polypeptide compound 3, i.p., n ═ 6/group; 6) model administration group (CCl)4) +150 μ g/kg polypeptide compound 4, i.p., n ═ 6/group; 7) model administration group (CCl)4) +150 μ g/kg of polypeptide compound 5, i.p., n ═ 6/group; 8) model administration group (CCl)4) +150 μ g/kg polypeptide compound 6, i.p., n-6/group. Wherein mice are administered 20% CCl4Control mice were given the same volume and frequency of corn oil injection at a dosing volume of 5.0 μ L/g of mouse body weight. The administration frequency is as follows: administration of CCl to mice4Once in three days for 6 weeks; when the model administration group is given to mice CCl4After 3 weeks, polypeptide compounds 1, 2, 3, 4, 5, 6 were administered for 3 weeks, respectively, starting at week 4. Wherein CCl4And Oil was purchased from Shanghai Allantin Biotechnology Ltd.
2. And (3) evaluating the drug effect:
in CCl4In the induced mouse hepatic fibrosis model, the mouse liver is characterized in that: there is inflammatory cell infiltration around the central venous area, edema and degeneration of liver cells, and large amount of collagen fiber deposition in the region of the junction and between the liver lobules. Three weeks after dosing, mice were treated and sampled, serological index testing was performed by retrobulbar venous bleeding, and liver tissue was taken for pathology analysis.
3. The experimental method comprises the following steps:
hematoxylin-eosin (H & E) staining: taking paraffin embedded tissue slices, and baking for 1h at 60 ℃. Dewaxing and hydrating: xylene 20 min → absolute ethanol 15 min → 95% ethanol 10min → 90% ethanol 5 min → 80% ethanol 5 min. Dyeing: hematoxylin for 7 minutes → tap water rinse clean → 1% hydrochloric acid ethanol differentiation 1s → tap water rinse → eosin staining 15s-20s → tap water rinse. And (3) dehydrating and transparency: 75% alcohol 1s → 85% alcohol 1s → 95% alcohol 1s → 100% alcohol 1s → xylene 1 s. The seal was air dried for 30 minutes and the gum was sealed.
Dyeing with sirius red: baking and dewaxing; standing in double distilled water for 5.0 minutes; dyeing with sirius red for 60-80 minutes in a dark room; rinsing with 0.5% glacial acetic acid for 5 s; dehydrating and transparentizing, sealing and taking a picture.
Immunohistochemistry: baking, dewaxing, and soaking in double distilled water for 5 min. Antigen retrieval: placing the rack for placing pathological sections in a buffer solution (PH is 6.0) beaker containing citric acid, and carrying out high temperature and high pressure for 15 minutes; the beaker was taken out, left to stand at room temperature until the temperature dropped to room temperature, then the sheet was taken out, put into 3.0% hydrogen peroxide for 10 minutes to block the endogenous peroxidase activity, and then washed 3 times with PBS for 5 minutes each. Tissues were blocked with 1.0% BSA for 1 h. Removing 1.0% BSA, adding Collagen I (type I Collagen) antibody on the tissue according to the recommended proportion of the instruction, and standing overnight at 4 ℃; taking out pathological sections the next day, adding a secondary antibody with horseradish peroxidase after the temperature is recovered, incubating for 60 minutes at 37 ℃, and then developing with DAB (diaminobenzidine) (TH & Ermo Scientific, USA); counterstaining with hematoxylin staining solution, washing with tap water for 5 minutes, differentiating with 1% hydrochloric acid ethanol, washing with tap water for 5 minutes, dehydrating, air-drying, sealing, and photographing (H & E staining solution and sirius red staining solution are from Shanghai Biotech engineering Co., Ltd., Collagen I antibody is from CST Co.).
In CCl4In the induced mouse hepatic fibrosis model, the mouse liver is characterized in that: there is inflammatory cell infiltration around the central venous area, edema and degeneration of liver cells, and large amount of collagen fiber deposition in the region of the junction and between the liver lobules.
In CCl4In the induced mouse liver fibrosis model, after 150 mug/kg of polypeptide compound 1, polypeptide compound 2, polypeptide compound 3, polypeptide compound 4, polypeptide compound 5 and polypeptide compound 6 are respectively administered, H of the mouse liver&The staining results are shown in FIG. 1; the results of sirius red staining and lipid accumulation analysis of mouse liver are shown in fig. 2 to 3; the immunohistochemical results of mouse livers are shown in FIGS. 4 to 5.
As can be seen from the results in FIG. 1, the aggregation of liver inflammatory cells of mice in each treatment model group is significantly improved after the mice with liver fibrosis are treated by the administration of the polypeptide compounds 1, 2, 3, 4, 5 and 6 of the present invention; liver fibrosis of mice in each model-administered group was significantly improved after administration of polypeptide compounds 1, 2, 3, 4, 5 and 6. The polypeptide compounds 1, 2, 3, 4, 5 and 6 can well inhibit the accumulation of ECM, and treat and improve liver fibrosis.
As can be seen from the results of FIGS. 2 and 3, the hepatic fibrosis mice treated with the polypeptide compounds 1, 2, 3, 4, 5 and 6 of the present invention showed significant therapeutic improvement in hepatic collagen deposition in the mice of each treatment model group.
As can be seen from the results of FIGS. 4 and 5, the expression level of the liver Collagen I of the mice of each treatment model group is obviously improved after the mice with liver fibrosis are treated by the administration of the polypeptide compounds 1, 2, 3, 4, 5 and 6 of the invention.
In conclusion, the polypeptide compound can obviously improve hepatic fibrosis and has good treatment effect on hepatic fibrosis.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof, and it is therefore intended that all such changes and modifications as fall within the true spirit and scope of the invention as defined by the appended claims be interpreted in accordance with the breadth to which they are fairly, if not explicitly recited herein.
Sequence listing
<110> Qing Yuan City chart microampere scientific and technological development Co., Ltd
Application of <120> polypeptide compound in preventing or treating hepatic fibrosis
<130> GD2390-21P125282
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 9
<212> PRT
<213> Artificial sequence
<400> 1
Cys Lys Lys Asn Ser Pro Thr Ala Cys
1 5
<210> 2
<211> 9
<212> PRT
<213> Artificial sequence
<400> 2
Cys Lys Lys Asn Tyr Pro Thr Leu Cys
1 5
<210> 3
<211> 9
<212> PRT
<213> Artificial sequence
<400> 3
Cys Lys Lys Asn Tyr Pro Thr Ala Cys
1 5
<210> 4
<211> 9
<212> PRT
<213> Artificial sequence
<400> 4
Cys Lys Lys Asn Ser Pro Thr Leu Cys
1 5
<210> 5
<211> 9
<212> PRT
<213> Artificial sequence
<400> 5
Cys Ser Lys Asn Tyr Pro Thr Leu Cys
1 5
<210> 6
<211> 9
<212> PRT
<213> Artificial sequence
<400> 6
Cys Ser Lys Asn Ser Pro Thr Leu Cys
1 5
<210> 7
<211> 9
<212> PRT
<213> Artificial sequence
<400> 7
Cys Ser Lys Asn Ser Pro Thr Ala Cys
1 5
<210> 8
<211> 9
<212> PRT
<213> Artificial sequence
<400> 8
Cys Ser Lys Asn Tyr Pro Thr Ala Cys
1 5
Claims (6)
1. The application of a polypeptide compound in preparing a medicament for preventing or treating hepatic fibrosis, wherein the polypeptide compound contains an amino acid sequence shown as the following:
Cys-Xaa2-Lys-Asn-Xaa5-Xaa6-Thr-Xaa8-Cys-COR1
wherein R is1=-NH2or-OH;
xaa2 ═ Lys or Ser;
xaa5 ═ Ser or Tyr;
xaa6 ═ Pro or Lys;
xaa8 ═ Leu or Ala.
2. The use of claim 1 wherein Xaa6 is Pro.
3. The use according to claim 2 wherein Xaa2 ═ Lys.
4. The use according to claim 1, wherein the polypeptide compound is any one of the following compounds 1 to 8:
compound 1(SEQ ID NO. 1):
Cys-Lys-Lys-Asn-Ser-Pro-Thr-Ala-Cys
compound 2(SEQ ID NO. 2):
Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Leu-Cys
compound 3(SEQ ID NO. 3):
Cys-Lys-Lys-Asn-Tyr-Pro-Thr-Ala-Cys
compound 4(SEQ ID NO. 4):
Cys-Lys-Lys-Asn-Ser-Pro-Thr-Leu-Cys
compound 5(SEQ ID NO. 5):
Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Leu-Cys
compound 6(SEQ ID NO. 6):
Cys-Ser-Lys-Asn-Ser-Pro-Thr-Leu-Cys
compound 7(SEQ ID NO. 7):
Cys-Ser-Lys-Asn-Ser-Pro-Thr-Ala-Cys
compound 8(SEQ ID NO. 8):
Cys-Ser-Lys-Asn-Tyr-Pro-Thr-Ala-Cys。
5. a composition comprising the polypeptide compound of any one of claims 1 to 4.
6. The composition of claim 5, wherein the composition is a pharmaceutical composition, optionally further comprising a pharmaceutically acceptable carrier or adjuvant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110087285.7A CN112891512B (en) | 2021-01-22 | Use of polypeptide compounds for preventing or treating liver fibrosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110087285.7A CN112891512B (en) | 2021-01-22 | Use of polypeptide compounds for preventing or treating liver fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112891512A true CN112891512A (en) | 2021-06-04 |
CN112891512B CN112891512B (en) | 2024-07-26 |
Family
ID=
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004067542A (en) * | 2002-08-02 | 2004-03-04 | Redox Bioscience Inc | Agent for treating acute hepatitis and chronic hepatic fibrogenesis |
WO2019085772A1 (en) * | 2017-11-06 | 2019-05-09 | 深圳市图微安创科技开发有限公司 | Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide |
CN110590929A (en) * | 2019-10-08 | 2019-12-20 | 吉林大学第一医院 | Application of TDGF-1 truncated body small molecule polypeptide in anti-hepatic fibrosis |
CN111068042A (en) * | 2018-10-18 | 2020-04-28 | 中山大学 | Application of polypeptide compound in preparation of drugs for treating nonalcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis |
CN111704653A (en) * | 2020-06-08 | 2020-09-25 | 中山大学 | Inhibitor polypeptide compounds targeted to fibronectin derived peptides and uses thereof |
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004067542A (en) * | 2002-08-02 | 2004-03-04 | Redox Bioscience Inc | Agent for treating acute hepatitis and chronic hepatic fibrogenesis |
WO2019085772A1 (en) * | 2017-11-06 | 2019-05-09 | 深圳市图微安创科技开发有限公司 | Treatment of biliary cirrhosis based on oxyntomodulin analogue glp-1r/gcgr dual-target agonist peptide |
CN109745549A (en) * | 2017-11-06 | 2019-05-14 | 深圳市图微安创科技开发有限公司 | The bis- target spot agonist polypeptides of GLP-1R/GCGR treat biliary cirrhosis |
CN111068042A (en) * | 2018-10-18 | 2020-04-28 | 中山大学 | Application of polypeptide compound in preparation of drugs for treating nonalcoholic liver disease, idiopathic pulmonary interstitial fibrosis and arteriosclerosis |
CN110590929A (en) * | 2019-10-08 | 2019-12-20 | 吉林大学第一医院 | Application of TDGF-1 truncated body small molecule polypeptide in anti-hepatic fibrosis |
CN111704653A (en) * | 2020-06-08 | 2020-09-25 | 中山大学 | Inhibitor polypeptide compounds targeted to fibronectin derived peptides and uses thereof |
Non-Patent Citations (1)
Title |
---|
MARIA MANGINI等: "Peptide-guided targeting of GPR55 for anti-cancer therapy", ONCOTARGET, vol. 8, no. 3, pages 1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway | |
AU2014278708B2 (en) | Tetrapeptides derived from human C-X-C chemokines useful for treatment of various skin conditions | |
CN111704653B (en) | Inhibitor polypeptide compound targeting fibronectin derived peptide and application thereof | |
CN106232616B (en) | Amphipathic synthetic antibacterial peptide, its medical composition and its use | |
Lee et al. | Silk protein hydrolysate increases glucose uptake through up-regulation of GLUT 4 and reduces the expression of leptin in 3T3-L1 fibroblast | |
CN102088992B (en) | Peptidyl diacylglycerides | |
CH637111A5 (en) | POLYPEPTIDE COMPOUNDS WITH THERMAL OR ANTAGONIST ACTIVITY AND METHODS OF SYNTHESIS THEREOF. | |
EP2125878B1 (en) | Short bio-active peptides for cellular and immunological modulation | |
CN113508126B (en) | Novel peptides and uses thereof | |
CN112898382A (en) | Polypeptide compound and application thereof in preventing or treating nonalcoholic steatohepatitis | |
CN112891512B (en) | Use of polypeptide compounds for preventing or treating liver fibrosis | |
WO2012013111A1 (en) | Angiogenesis-inhibiting peptide and application thereof | |
CN112891512A (en) | Application of polypeptide compound in preventing or treating hepatic fibrosis | |
CN104558150A (en) | Novel growth hormone releasing hormone analog peptides and application thereof in preparing medicines for treating infertility | |
KR20180058843A (en) | Short synthetic peptides and uses thereof | |
AU2021200731B2 (en) | Pro-drug peptide with improved pharmaceutical properties | |
CN112625093B (en) | Polypeptide compound for preventing and/or treating nonalcoholic steatohepatitis | |
EP2552940A2 (en) | Peptides for promoting angiogenesis and an use thereof | |
KR20080016675A (en) | Cell nucleus-entering compostions | |
WO2022178841A1 (en) | Combination of adiponectin receptor agonist and elastin receptor inhibitor for prevention or treatment of non-alcoholic fatty liver disease | |
US20100215583A1 (en) | Cell nucleus-entering compositions | |
CN113603761B (en) | Small molecule polypeptide for treating intestinal dysfunction of severe acute pancreatitis | |
CN117088942A (en) | Polypeptide compound for improving liver fibrosis and application thereof | |
RU2110275C1 (en) | Method of synthesis of peptide showing anabolic activity, stimulating body mass increase, development of epidermal layer and hair growth | |
CN118403146A (en) | Application of polypeptide PEP-Z-2 in preparation of medicines for treating kidney fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |